Literature DB >> 35178095

Ischemic Priapism Progressing to Penile Gangrene in a Patient with COVID-19 Infection: A Case Report with Literature Review.

Saad M Alsaedi1, Rakan M Alsarwani1, Ahmed I Ali2, Saleem A Aladhrai3.   

Abstract

Priapism is considered a rare disorder and even more rare when it occurs as a complication of COVID-19. To the best of our knowledge, only eight studies have reported priapism as a complication of COVID-19. Here, we report the case of a 66-year-old male with COVID-19 who presented with neglected priapism for three days. On local examination, penile erection was apparent in association with blackened areas on the glans penis extending to the midpenile shaft denoting penile gangrene. A clear line of demarcation was noticed at the midpenile shaft. Penile duplex was performed, showing no blood flow in both cavernosal arteries. Penile aspiration was performed, and the cavernosal blood sample showed evidence of ischemic priapism. Given the presence of penile gangrene extending to the midshaft of the penis and the poor general condition of the patient, the decision was made to perform partial penectomy and suprapubic tube placement. We recommend the establishment of a guideline for the diagnosis and prevention of thrombotic diseases in patients with COVID-19 infection as there is increasing evidence of COVID-19-related thrombotic manifestations.
Copyright © 2022 Saad M. Alsaedi et al.

Entities:  

Year:  2022        PMID: 35178095      PMCID: PMC8847035          DOI: 10.1155/2022/8408216

Source DB:  PubMed          Journal:  Case Rep Med


1. Introduction

A novel coronavirus (CoV) emerged in Wuhan, China, at the beginning of December 2019, named “COVID-19” by the World Health Organization (WHO) [1]. It causes a range of respiratory and gastrointestinal symptoms, including fatigue, cough, and fever that may progress to severe respiratory failure [2]. Other life-threatening complications include venous and arterial thromboembolism [3]. Pulmonary embolism (PE) is recognized as the most common thrombotic manifestation, while arterial events have been reported less frequently [4]. Priapism is considered a rare disorder [5] and even more rare when it occurs as a complication of COVID-19. To the best of our knowledge, only eight studies have reported priapism as a complication of COVID-19 [6-13]. Here, we report a case of a 66-year-old male with COVID-19 who presented with neglected priapism for three days and penile gangrene.

2. Case Presentation

A 66-year-old male patient presented to the emergency room (ER) with shortness of breath, cough, and generalized fatigue for two days; he tested positive for COVID-19 infection. However, he had a stable O2 saturation and was discharged accordingly. Five days following discharge, the patient represented to the ER with shortness of breath and neglected priapism of three days duration. On his second ER visit, his O2 sat was 78% on room air, 92-93% on 15 L/min nonrebreather mask, blood pressure was 126/81 mmHg, respiratory rate was 21/min, pulse rate was 110 beats per minute, and body temperature was 36.9°C. His Glasgow Coma Scale (GCS) score was 15 out of 15. On examination, the patient was conscious and distressed. A priapism was observed together with blackened areas on the glans penis extending to the midpenile shaft denoting penile gangrene. A clear line of demarcation was noticed at the midpenile shaft. The patient's medical history included type 2 diabetes mellitus (DM), hypertension (HTN), ischemic cardiomyopathy, and chronic kidney disease (CKD): stage 3b with baseline creatinine 1.5-1.6 mg/dL, atrial fibrillation, an old cerebrovascular accident (CVA) with no residual weakness apart from baseline expressive aphasia, and depression. The patient's medications included amlodipine, insulin NovoMix, and hydralazine. He had also been taking warfarin 7.5 mg once daily and risperidone 0.25 mg and mirtazapine 30 mg once daily as needed for the past five years. Laboratory findings at admission showed leukocytes of 10.70 × 10 e3/uL (4.00–11.00), hemoglobin 11.1 g/dL (13.5–17.2), platelet count 220 × 10 e9/L (150–450), prothrombin time (PT) 90 sec (11.0–15.0), international normalized ratio (INR) 7.19 (0.89–1.10), C-reactive protein (CRP) 219.50 mg/L (0.00–5.00), creatinine 244.20 umol/L (60.00–115.00), urea in serum 23.50 mmol/L (3.00–9.20), D-dimer 20.0 mg/L (0.0–0.5), and a positive COVID-19 polymerase chain reaction (PCR) test. Penile duplex was performed and showed no blood flow in both cavernosal arteries. Magnetic resonance imaging (MRI) for the penis was requested to evaluate for necrosis but was unavailable in the hospital, and the patient could not be transferred due to his desaturation status.

2.1. Therapeutic Intervention

On admission, warfarin was withheld, and vitamin K 10 mg IV was administered together with four units of fresh frozen plasma (FFP) to correct his elevated INR. He also received dexamethasone 6 mg IV and ceftriaxone 2 gm IV infusions. The patient was then admitted under the intensive care unit/internal medicine (ICU/IM) for further management of his COVID-19 infection and warfarin toxicity. A suprapubic tube was placed to relieve urinary retention by the urology team, who further recommended penile aspiration/surgical intervention after INR correction. Later, in the same day, the patient developed hypoxia and was connected to high flow nasal canula (HFNC): FLOW 60, FIO2 100%, and stabilized. His INR had reduced from 7.14 to 1.70, and anesthesia consultation was done for surgical approval. The patient was taken to the operating theatre (OR), and as he was very agitated and a trial of a local penile block was not feasible, general anesthesia was introduced. Penile aspiration was performed, and the cavernosal blood sample showed evidence of ischemic priapism. However, penile aspiration was not successful to alleviate his erection. Given the intraoperative findings and the patients' poor general condition, it was decided to perform a partial penectomy. Postoperatively, he was kept intubated and mechanically ventilated for three days, at which point he was successfully extubated. Eventually, he was discharged home with O2 maintained on room air.

3. Discussion

Priapism is a penile erection that lasts four hours or longer and is unrelated to sexual stimulation [14]. Priapism is grouped into three types: ischemic type (which requires immediate clinical intervention), nonischemic type, and stuttering (recurrent) priapism. Ischemic priapism (also known as venoocclusive priapism) is characterized by a painful penile erection which persists for a prolonged time leading to little or no blood flow to the corporal bodies [15]. Priapism can result from conditions associated with increased blood viscosity such as sickle cell disease and hematological malignancies [16], and hyperviscosity in patients with COVID-19 has been previously reported in the literature [17, 18], possibly accounting for the development of priapism in COVID-19 patients. Moreover, COVID-19 is known to cause hypercoagulability although the underlying mechanisms for this are not well understood. Hypotheses include cytokine storm, complement activation, shutdown of fibrinolysis, and COVID-19 itself activating the coagulation cascade. Excessive release of cytokines causes thrombosis through a variety of processes, including the activation of monocytes, neutrophils, and the endothelium. All of these mechanisms can contribute to the prothrombic state [4, 19]. It has been documented that COVID-19 patients can develop thrombotic events even when they are anticoagulated. Therefore, screening for thromboembolic events is essential in such patients [20]. In our literature review, we found eight cases of ischemic priapism, including one case of stuttering ischemia associated with COVID-19 infection (Table 1). Reported cases included patients ranging in age from 34 to 69 years, of whom one was also undergoing warfarin therapy, as in the current case. By comparison to our case, however, priapism did not progress to gangrene in any of the previously reported cases nor did any patient require surgery. No known risk factor for priapism was reported in four cases, and detumescence was achieved with an intracavernosal injection in five of the eight cases.
Table 1

Documented cases of priapism related to COVID-19 infection in the literature.

StudyAge (y)Type of priapismDuration of priapismICU admissionDrug historyMedical history/comorbiditiesTreatment of priapismFollow-up/outcomePurported priapism risk factors
Lam et al., 2020 [6]67IschemicUnknown durationN/AWarfarinDilated cardiomyopathy of unknown etiology, left bundle branch block, cutaneous scleroderma, paroxysmal atrial fibrillation, DM type 2, and iron deficiency anemiaConservativeDied due to clinical deteriorationMinor trauma
Warfarin
Silverman et al., 2021 [7]69IschemicUnknown duration (>3 hours)YesN/AObesityIntracavernosal phenylephrine injectionAchieved detumescence, but eventually died due to clinical deteriorationPropofol
Lamamri et al., 2021 [8]62IschemicUnknown duration (>4 hours)YesNoneLeft inguinal surgery and appendectomyIntracavernosal ethylephrine injectionAchieved detumescence and was discharged to wardNone
Addar et al., 2021 [9]62Ischemic10 daysYesN/AHTN and dyslipidemiaIntracavernosal phenylephrine injectionAchieved detumescence and was discharged homeNone
Carreño et al., 2021 [10]39Ischemic3 daysYesNoneOverweightIntracavernosal adrenaline injectionFailed to achieve detumescence and eventually died due to clinical deteriorationPropofol
Grimberg et al., 2021 [11]45Stuttering ischemic priapismUnknown duration (>4 hours)N/AN/AHTN and benign prostatic hyperplasiaIntracavernosal phenylephrine injectionAchieved detumescence, but had recurrence 8 h later and was managed with another intracavernosal phenylephrine injection. He achieved detumescence eventually with no recurrence afterward. He was discharged homeNone
Larrarte-arenas et al., 2021 [12]65Ischemic30 hoursNoNifedipine, prazosin, calcitriol, subcutaneous erythropoietin, and unfractionated heparinChronic kidney disease on hemodialysis, HTN, secondary hyperparathyroidism, and anemiaIntracavernosal epinephrine injectionAchieved detumescenceRenal replacement therapy
Prazosin
Giuliano et al., 2021 [13]34Ischemic36 hoursNoNoneNoneInitially, intracavernosal phenylephrine injection (failed to achieve detumescence). Then, a bilateral T-shunt procedure was performed.The bilateral T-shunt helped to achieve detumescence, and the patient was discharged home. However, it was complicated by complete erectile dysfunction after 3 months of follow-upNone
Our case66Ischemic priapism progressed to penile gangrene3 daysYesAmlodipine, insulin NovoMix, hydralazine, warfarin, risperidone, and mirtazapineDM type 2, HTN, ischemic cardiomyopathy, chronic kidney disease, atrial fibrillation, cerebrovascular accident, and depressionPartial penectomyThe patient improved and eventually was discharged homeWarfarin
Antidepressant/antipsychotic
In our presented case, there were many risk factors for developing priapism other than COVID-19 infection, including unopposed warfarin action and antidepressant medication. However, it is only COVID-19 that had a recent onset in our patient compared to his long-term use of antidepressants and warfarin. Regardless of the cause, however, priapism rarely progresses to penile gangrene [21]. Other studies have also suggested that priapism was most likely induced by COVID-19 infection rather than other factors [6-8]. All of these evidences strongly suggest the need for the diagnosis and prevention of thrombotic diseases in at-risk patients with COVID-19 infection.
  18 in total

Review 1.  Guideline of guidelines: priapism.

Authors:  Asif Muneer; David Ralph
Journal:  BJU Int       Date:  2016-12-29       Impact factor: 5.588

2.  Blood viscosity of COVID-19 patient: a preliminary report.

Authors:  Beuy Joob; Viroj Wiwanitkit
Journal:  Am J Blood Res       Date:  2021-02-15

3.  A Peculiar Case of Priapism: The Hypercoagulable State in Patients with Severe COVID-19 Infection.

Authors:  Germain Lam; Rowan McCarthy; Rana Haider
Journal:  Eur J Case Rep Intern Med       Date:  2020-07-14

4.  Anticoagulant-induced priapism progressing to penile gangrene: a devastating complication!

Authors:  Deepak Sharanappa Nagathan; Harvinder Singh Pahwa; Awanish Kumar; Apul Goel
Journal:  BMJ Case Rep       Date:  2012-11-21

5.  High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients.

Authors:  Jean-François Llitjos; Maxime Leclerc; Camille Chochois; Jean-Michel Monsallier; Michel Ramakers; Malika Auvray; Karim Merouani
Journal:  J Thromb Haemost       Date:  2020-05-27       Impact factor: 5.824

Review 6.  Novel coronavirus disease (COVID-19): a pandemic (epidemiology, pathogenesis and potential therapeutics).

Authors:  Saima Hamid; Mohammad Yaseen Mir; Gulab Khan Rohela
Journal:  New Microbes New Infect       Date:  2020-04-14

Review 7.  COVID-19 and Hypercoagulability: A Review.

Authors:  Asim Kichloo; Kirk Dettloff; Michael Aljadah; Michael Albosta; Shakeel Jamal; Jagmeet Singh; Farah Wani; Akshay Kumar; Srilakshmi Vallabhaneni; Muhammad Zia Khan
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

8.  Priapism in a patient with coronavirus disease 2019 (COVID-19): A case report.

Authors:  Myriam Lamamri; Ala Chebbi; Jordan Mamane; Sofia Abbad; Milena Munuzzolini; Florence Sarfati; Stéphane Legriel
Journal:  Am J Emerg Med       Date:  2020-06-18       Impact factor: 2.469

9.  Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis.

Authors:  Steeve Provencher; Jean-Christophe Lega; Boun Kim Tan; Sabine Mainbourg; Arnaud Friggeri; Laurent Bertoletti; Marion Douplat; Yesim Dargaud; Claire Grange; Hervé Lobbes
Journal:  Thorax       Date:  2021-02-23       Impact factor: 9.139

10.  Therapeutic plasma exchange for COVID-19-associated hyperviscosity.

Authors:  Alexander D Truong; Sara C Auld; Nicholas A Barker; Sarah Friend; A Thanushi Wynn; Jason Cobb; Roman M Sniecinski; Christin-Lauren Tanksley; Derek M Polly; Manila Gaddh; Michael Connor; Hirotomo Nakahara; H Clifford Sullivan; Christine Kempton; Jeannette Guarner; Alexander Duncan; Cassandra D Josephson; John D Roback; Sean R Stowell; Cheryl L Maier
Journal:  Transfusion       Date:  2020-12-09       Impact factor: 3.337

View more
  2 in total

Review 1.  SARS-CoV-2 Effects on the Male Genitourinary System.

Authors:  Zachary M Connelly; Dustin Whitaker; Alexandra Dullea; Ranjith Ramasamy
Journal:  Am J Clin Exp Urol       Date:  2022-08-15

2.  Coronavirus disease 2019 (COVID-19) and priapism: An unexplored association.

Authors:  Dominic Mpumelelo Malinga; Abdullah E Laher; Jared McDowall; Ahmed Adam
Journal:  Curr Urol       Date:  2022-06-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.